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Abstract
The initiation of premalignant lesions is associated
with subtle cellular and gene expression changes.
Here we describe a severe combined immunodeficient
mouse xenograft model with human adult skin and
compare chemical carcinogenesis and wound healing.
We focus on a secreted binding protein for fibroblast
growth factors (FGF-BP) that enhances the activity of
locally stored FGFs and is expressed at high levels in
human epithelial cancers. Carcinogen treatment of
murine skin induced papilloma within 6 weeks, where-
as the human skin grafts displayed no obvious
macroscopic alterations. Microscopic studies of the
human skin, however, showed p53-positive keratino-
cytes in the epidermis, increased angiogenesis in the
dermis of the treated skin, enhanced proliferation of
keratinocytes in the basal layer, and an increase of
FGF-BP protein and mRNA expression. In contrast,
after surgical wounding of human skin grafts or of
mouse skin, FGF-BP expression was upregulated
within a few hours and returned to control levels after
2 days with wound closure. Enhanced motility of
cultured keratinocytes and dermal fibroblasts by
FGF-BP supports a role in wound healing. We
conclude that adult human skin xenografts can be
used to identify early molecular events during malig-
nant transformation as well as transient changes
during wound healing.
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Introduction
Although the use of various animal models has provided
remarkable insights into the mechanisms of skin carcino-
genesis [1], differences in skin morphology, life span of the
species, extent of DNA repair, and capacity to metabolize
chemical carcinogens have made the extrapolation of these
results to human beings rather limited [2–4]. More recently,
cellular interactions and molecular events occurring during
carcinogenesis of human skin have been facilitated by the
use of human skin grafts in severe combined immunodeficient
(SCID) mice [5–7] and the human skin/SCID mouse model
proved to be appropriate for diverse studies including those on
human endothelium during inflammation [5], interactions be-
tween normal and malignant human cells [7], wound healing
[8], and viral effects [9–11]. Interestingly, whereas in mouse
skin the application of chemical carcinogens can produce
squamous atypia or carcinoma, this effect was not observed
in xenografted human neonatal foreskin [12,13]. The occur-
rence of human squamous carcinomas on such xenografts was
observed very rarely and only after application of a carcinogen
(dimethyl[a]benzanthracene, DMBA) with subsequent UVB
promotion [12]. However, more recent studies showed that
angiogenesis is an early event during chemical carcinogenesis
of murine skin [14] and we wondered to what extent this might
also be true for a human model because it is commonly
believed that tumor angiogenesis is a rather early event that
occurs at the transition of premalignant lesions to invasive
cancer [15,16] (reviewed in Ref. [17]).
Many features of solid tumors such as the release of growth
factors, proliferation of stromal cells and vascular remodeling
or angiogenesis are reminiscent of healing wounds [18].
Among other factors, fibroblast growth factors (FGFs) have
been shown to be major players in skin wound healing and in
squamous cell carcinogenesis [1,19,20]. A rate-limiting role for
FGF-2 in wound healing is supported by the inhibitory effect of
blocking antibodies to FGF-2 [21], and wound healing is
delayed in FGF-2 knockout animals [22]. However, no signif-
icant changes of FGF-2 or FGF receptor levels were found
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during the wounding process [23], suggesting that modula-
tion of the activity status of FGF signaling could be brought
about independent of changes in expression levels of the
growth factor.
In earlier studies, we and others observed that human
squamous cell carcinomas (SCCs) express FGF-2 together
with high levels of a secreted FGF-binding protein (FGF-BP)
that is found at high levels during the perinatal phase of
development and downregulated thereafter [24–28]. We
also detected FGF-BP upregulation with high frequency
early during colon carcinogenesis, i.e., in dysplastic lesions
[29] and during malignant progression of breast cancer [30].
Overexpression of the FGF-BP cDNA in nontumorigenic
human SW-13 cells induced these cells to form highly
vascularized tumors [25] and depletion of endogenous
FGF-BP from human SCC or colon cancer cells reduced
their growth as xenografted tumors in mice [31]. Based on
these data and studies from others as well as from our
laboratory [25,27,31–34], the current working model propo-
ses that FGF-BP functions as an extracellular chaperone for
FGFs that enhances the activity of locally immobilized FGFs.
FGF-BP upregulation thus could be a mechanism for FGF
activation during malignant progression and also serve as an
early indicator of malignant transformation of epithelial cells.
We hypothesized that changes in FGF-BP expression
levels could be apparent during wound healing as well as
during skin carcinogenesis and we studied FGF-BP modu-
lation during early stages of carcinogenesis compared with
wound healing in human and murine skin. We used full-
thickness adult upper eyelid skin as the human xenograft,
which was grafted onto SCID mice and after healing treated
with chemical carcinogens either by repeated application of
DMBA or DMBA plus 12-O-tetradecanoylphorbol-13-acetate
(TPA). We show an upregulation of FGF-BP in the human
epidermis as early as 4 weeks after start of the treatment.
Concomitantly, we found p53-positive keratinocytes in the
epidermis, an increased number of blood vessels in the
dermis of the treated skin, and enhanced proliferation of
epidermal keratinocytes in the basal layer. In parallel studies,
we observed a strong upregulation of FGF-BP expression
within 7 hours of skin wounding, which returned to control
levels after 2 days, and we show that FGF-BP can stimulate
keratinocyte and dermal fibroblast motility in cell culture,
suggesting a possible role during wound closure.
Materials and Methods
Antibody Generation and Purification
Rabbit anti–FGF-BP antibodies against a glutathione-S-
transferase (GST)–FGF-BP fusion protein [34] were gener-
ated by Lampire Biological Laboratories (Pipersville, PA)
according to a standard protocol comprising subcutaneous
and intradermal injection of 500 mg antigen in Freund’s
complete adjuvant. After three booster injections with the
same amount of antigen in Freund’s incomplete adjuvant,
the rabbit was bled to obtain antiserum. Antigen-affinity
purification of the antibodies was performed using eukaryotic,
recombinant His-tagged FGF-BP that was produced in SF9
insect cells [34] and coupled to Reacti-Gel (Pierce, Rockford,
IL) according to the manufacturer’s protocol. When using
100 mg His-tagged FGF-BP and 4 ml antiserum, approxi-
mately 200 mg of antibodies was obtained. In Western blots,
these antibodies as well as the antiserum recognized the
recombinant FGF-BP from insect cells [34] and bacterial cell
lysates. To further demonstrate the specificity of the affinity-
purified anti–FGF-BP antibodies, ME-180 and SW-13 cells
were stained by immunofluorescence. The FGF-BP positive
ME-180 cells showed strong staining in the cytoplasm, in
contrast to the FGF-BP negative SW-13 cells (data not
shown).
Skin Xenografts
CB-17 SCID (scid/scid) mice (Taconic, Germantown,
NY), 6 to 8 weeks old, were used for xenografting. Human
upper eyelid skin discarded after plastic surgery was used for
grafting at the day of removal. Grafting was performed after
advice from the Herlyn laboratory (Wistar Institute, Philadel-
phia, PA) as published in Ref. [35]. Briefly, after shaving the
hair from a 5-cm2 area on each side of the lateral abdominal
region, full-thickness skin was removed, creating two circular
graft beds (1.5 cm in diameter). Full-thickness human skin
grafts of the same size were placed onto the wound beds.
The transplants were held in place with 6-0 nonadsorbable,
monofilament suture material and covered with a Band-Aid
clipped to the dorsal and ventral skin of the animal with a
surgical staple. An additional layer of micropore cloth tape
was applied.
Wound Healing Experiments
In vivo wound healing assay Wounding experiments were
performed on mouse skin and on viable human skin patches
that were grafted onto SCID mice. Skin wounding was
performed by full-thickness incision of the shaven skin with
a scalpel. Skin from within 2 mm of the wound area was
removed after different time points and control skin was
obtained from an area about 0.5 to 1 cm apart from the
wound and processed for paraffin embedding or immediately
used for RNA isolation.
In vitro ‘‘wounding’’ assay SW-13 cells (FGF-BP negative,
FGF-2 positive), SW-13/FGF-BP transfected cells [25], pri-
mary mouse keratinocytes (MKs) and primary mouse dermal
fibroblasts (MDFs) were used. Primary cells were prepared
from day 3 postnatal mice as described [36]. A total of 105
cells were plated in triplicates for each of at least three
independent experiments into six-well plates to reach con-
fluence after 16 hours when an x-shaped area was scraped
from the confluent monolayer using a yellow pipet tip. Cell
motility was measured in the presence or absence of FGF-
BP (100 ml partially purified fraction), FGF-2 (5 ng/ml; Life
Technologies, Rockville, MD), or both. Closure of the gap
was photographed every 12 hours for 3 days. FGF-BP was
partially purified by heparin fractionation using conditioned
medium from transfected SW-13/FGF-BP cells as described
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[25]. An equally prepared fraction from SW-13 cells trans-
fected with an empty vector (SW-13/Co) served as a control.
Carcinogenesis Experiments
Application of chemical carcinogens or control solvent
was started 2 weeks after xenograft implantation for 6 weeks
and the experiment was terminated 2 weeks after the last
treatment. On the human skin xenografts and adjacent
mouse skin of the SCIDmice, 200 mgDMBA in 200 ml acetone
was applied topically and this treatment was repeated once a
week for 6 weeks (DMBA alone) (n = 9). In a parallel protocol,
DMBA was only applied once followed 3 days later by twice
weekly topical application of 10 mg TPA/200 ml acetone for 6
weeks (n = 9). Control grafts were treated with acetone alone
(n = 5). At the end of the experiment (week 10 post grafting, 2
weeks after the last treatment), mice were sacrificed, skin
pieces removed, and immediately frozen for RNA analysis,
or fixed in 10% formalin and embedded in paraffin.
Histology and Immunohistochemistry
Human skin grafts were harvested 6 and 10 weeks post
grafting. Paraffin-embedded sections were stained as de-
scribed recently [28,37]. Briefly, sections were microwaved
for 10 minutes and after 5 minutes cooling at room temper-
ature treated with fresh xylene for 10 minutes. After a
duplicate wash in 100% ethanol for 5 minutes each, the
slides were rehydrated by gradient ethanol washing and then
washed in double-distilled H2O and 1  PBS for 1 minute
each. Heat treatment was performed in 1  PBS/1% (vol/
vol) acetic acid for 10 minutes, reaching 80jC. The slides
were then transferred to warm (80jC) 1  PBS and incu-
bated for 20 minutes before blocking peroxidases with 0.3%
H2O2 in 1  PBS at 4jC for 20 minutes. After two washes in
1  PBS the tissue was treated in 1  PBS/1% BSA and
blocked in a humid chamber with 10% horse or goat normal
serum, depending on the secondary antibodies’ origin, in
1  PBS/2% BSA. After washing in PBS/2% BSA for 5
minutes, primary antibodies were applied for 20 minutes in a
50jC incubator: anti–FGF-BP 100 mg/ml, anti-p53 (Onco-
gene Research Products, Boston, MA) 1:200, anti–prolifer-
ating cell nuclear antigen (PCNA; Signet Laboratories,
Dedham, MA) 1:200, or anti-human CD31 (DAKO, Carpin-
teria, CA) 1:200. As a secondary antibody, biotinylated goat
anti-rabbit or biotinylated rabbit anti-mouse in 1  PBS/2%
BSA was applied for 20 minutes at room temperature. For
detection and visualization, the ABC system (Vector, Burlin-
game, CA) was used according to the manufacturer’s proto-
col with 0.1 mg/ml DAB as substrate. Sections were stained
with hematoxylin and eosin. For quantitation of blood ves-
sels, CD31-positive vessels were counted. At least five
sections per treatment were scored containing 5 to 10 fields
at a magnification of 250  in a blinded fashion.
In Situ Hybridization
Sense and antisense digoxigenin-labeled (Roche, Man-
nheim, Germany) riboprobes for human FGF-BP were tran-
scribed in vitro for 2 hours at 42jC in the presence of 0.25 mM
digoxigenin conjugated dUTP from 1 mg of linearized plasmid
containing full-length cDNAs. Transcripts were treated with
RNase-free DNase I, ethanol-precipitated, and resuspended
in 100 ml DEPC-treated water. In situ hybridization (ISH) was
performed as described before [26] with the modifications
outlined below. Briefly, 10-mm-thick tissue sections on silan-
ized slides were washed, acetylated, and treated overnight
at 55jC with hybridization buffer containing heat-denatured
sense or antisense riboprobes. Sections were washed after
hybridization at high stringency, immersed in blocking buffer,
and immunohistochemistry was performed using an alkaline
phosphatase-conjugated sheep anti-digoxigenin antibody
(1:500), following the manufacturer’s instructions (Roche,
Mannheim, Germany). Chromogen substrate for alkaline
phosphatase (NBT/BCIP) was added and the reaction was
allowed to proceed overnight at 4jC. Color development was
stopped with 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA, and
tissue was mounted in an aqueous mounting medium.
Northern Analysis
RNA was isolated from skin samples using RNAStat (Tel-
Test, Friendswood, TX). Twenty micrograms of total RNA
from each tissue sample were separated in an agarose gel
and transferred onto nitrocellulose. Blots were hybridized
with a 32P-labeled, full-length cDNA probe for human or
mouse FGF-BP, respectively. For quantitation, the blots
were stripped and reprobed with a 32P-labeled, 0.5-kb cDNA
fragment of the glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) housekeeping gene (Clontech, Palo Alto,
CA). Hybridization was carried out in a buffer containing
50% formamide at 42jC. Blots were subsequently washed in
0.1  SSC and 0.1% SDS at 65jC before exposure to
phosphorimaging plates. Plates were scanned (Phosphoim-
ager 445S1; Molecular Dynamics, Sunnyvale, CA) and
quantifiedusing ImageQuant software (MolecularDynamics).
Data Analysis
The Graphpad Prism 3.0 software was used for data
analysis. Student t tests were applied for single comparisons
and ANOVA for multiple comparisons. Correlations of non-
parametric data were analyzed by chi-square analysis.
P values smaller than .05 were considered statistically
significant.
Results
Development of Papilloma on the Murine but Not the
Human Skin
We used the SCID/human skin xenograft model to study
whether upregulation of FGF-BP might be a step during
squamous cell carcinogenesis and thus provide an enhancer
of local FGF activity we recently described for the recombi-
nant protein [34]. Human upper eyelid skin grafts and adja-
cent mouse skin were treated with either DMBA alone for
6 weeks (n = 9) or with DMBA/TPA for 6 weeks (n = 9).
Six weeks after starting topical treatment of the skin grafts all
of the treated mice (18/18) but none of the control mice
(5/5) showed papilloma with dysplasia on the mouse skin
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(Figure 1a, arrows; P < .0001 treated vs. control, chi-square
test). At the same time none of the human skin xenografts
showed any gross macroscopic alterations (Figure 1a) ex-
cept for a slight thickening of the carcinogen-treated grafts
(see Figure 1a vs. Figure 3a). Histological staining of the
treated human xenografts after 4 weeks of treatment and at
the end of the experiment at 10 weeks post grafting revealed
microscopically evident subtle morphologic changes in the
epidermis and dermis that are commonly associated with
incipient neoplasia, such as hyperplasia and moderate dys-
plasia, but none of the control-treated grafts showed similar
microscopic changes (not shown). The human skin grafts
were viable even 10 weeks after transplantation independent
of the treatment protocols.
Upregulation of FGF-BP in Carcinogen-Treated Murine and
Human Skin
The appearance of preneoplastic histologic features in
the human skin was accompanied by a dramatic increase of
FGF-BP levels in the tissues. Most significantly, all of the
treated grafts (18/18) showed a strong staining for FGF-BP
protein in the entire epidermis at 4 weeks of treatment, which
persisted for at least 2 weeks after the last treatment with
DMBA (Figure 1f ) or DMBA/TPA, when the experiments
were discontinued at 10 weeks post grafting. Furthermore,
sebaceous glands, blood vessel endothelium, sweat glands,
and hair follicles expressed FGF-BP in the treated skin (not
shown). In contrast, control xenografts without carcinogen
treatment showed very low to undetectable FGF-BP expres-
sion (Figure 1e). In situ hybridization validated that the FGF-
BP mRNA is upregulated in parallel with the protein (Figure
1, b–d ). These results in the human skin xenografts were
corroborated by a parallel upregulation of FGF-BP in the
adjacent mouse skin (not shown). Interestingly, the induction
of FGF-BP expression was similar between the two different
carcinogenesis protocols (DMBA alone or DMBA plus TPA),
suggesting that mutagenesis induced by DMBA is sufficient
to upregulate FGF-BP gene expression and does not require
the tumor promoter TPA.
Vascular Density, Basal Cell Proliferation, and p53 Expres-
sion in Preneoplastic Human Skin
Because FGF-BP was shown to mobilize dormant FGFs
and enhance their activity [25,27,31,34,37], we hypothesized
Figure 1. Effect of carcinogen treatment on FGF-BP, PCNA and p53. (a) SCID mouse with human skin xenograft (arrowhead) treated with DMBA/TPA at 6 weeks
of treatment. Carcinogen-induced papilloma on the mouse skin are indicated by the arrows. (b–d) in situ hybridization for human FGF-BP mRNA. (b) Sense probe;
(c, d) antisense probe; (e, f) immunohistochemical detection of the FGF-BP protein; (g, h) staining for PCNA and (i, j) staining for p53. Samples from control- (c,
e, g, i) and DMBA-treated xenograft skin (b, d, f, h, j) were taken at the end of the experiment (i.e., 2 weeks after the last topical treatment and a total of 10 weeks
after the initial grafting).
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that upregulation of FGF-BP might be paralleled by in-
creased blood vessel density as well as keratinocyte prolif-
eration in skin xenografts. Indeed, concomitant with the
upregulation of FGF-BP during the carcinogen treatment,
we found a significant 2- to 2.5-fold increase in the number of
microvessels beneath the epidermis as visualized by stain-
ing with the human endothelial cell marker CD31 (Figure 2a).
In addition to increased vessel density, strong expression of
the PCNA in keratinocytes in the basal and squamous cell
layer of the carcinogen-treated grafts was observed. Control
xenografts were either negative or only weakly positive for
PCNA (Figure 1, g and h). Furthermore, immunohistochem-
ical examination of the xenografts for nuclear p53 expression
revealed strong nuclear staining for p53 in all of the carcin-
ogen-treated xenografts but not in the controls (Figures 1, i
and j, and 2b). Again, no significant difference between the
DMBA alone and the DMBA plus TPA protocol was apparent.
p53-positive keratinocytes appeared predominantly in the
basal layer and in the first layers of the squamous stratum at
this time point, i.e., 2 weeks after the last treatment and 10
weeks post grafting (Figure 1j ).
FGF-BP Upregulation during Wound Healing In Vivo
Wound healing shares a number of aspects with tumor-
igenesis, and tumors have been described as nonhealing or
chronic wounds. To determine whether FGF-BP would be
regulated during wound healing and if this regulation is
transient or continuous, we used the human upper eyelid
skin grafts as a model (Figure 3a). After ingrowth of tissue
grafts, full-thickness wounds were cut and biopsied at differ-
ent time points after wounding to monitor FGF-BP mRNA
levels by Northern blotting and FGF-BP protein by immuno-
histochemistry. Whereas FGF-BP mRNA and protein in the
undamaged grafted skin were low, mRNA rapidly increased
up to 17-fold 7 hours after wounding and returned to back-
ground levels within 4 days (Figure 3b). FGF-BP protein
expression follows this course (not shown). A similar transi-
tory upregulation of FGF-BP during the initial phase of wound
healing was observed in parallel studies with mouse skin
(not shown).
The transient appearance of FGF-BP in the healing
wound suggested to us a potential stimulatory activity on
cell motility during the initial healing phase and we thus
tested whether FGF-BP can affect motility of dermal fibro-
blasts and keratinocytes in an in vitro assay. In this assay,
confluent monolayers of FGF-2–expressing primary MKs
and MDFs as well as human epithelial SW-13 cells were
scraped with the tip of a pipette, and the filling of the scraped
areas with cells was monitored. Addition of FGF-2 alone had
no significant stimulatory effect on cell motility in the absence
of FGF-BP (not shown). However, the presence of FGF-BP
promoted the filling in of monolayers of all three cell types
(Figure 3c). The most dramatic effect was observed with
FGF-BP transfected SW-13 cells, where closure of the gap
was completed after 24 hours compared with approximately
96 hours in the control cells that do not express FGF-BP (4-
fold faster closure). The effect of FGF-BP on time to closure
of the gap was 3-fold for MDF and 2.5-fold for MK cells.
These studies corroborate earlier findings in which addition
of FGF-BP enhanced FGF-2–induced chemotaxis of human
endothelial cells [38].
Discussion
The human skin/SCID mouse model was used to elucidate
early stages of skin carcinogenesis in comparison to molec-
ular changes initiated during wound healing in human and
murine skin. We show here that in the human skin derived
from adults the topical application of chemical carcinogens is
sufficient to induce early preneoplastic stages comparable
Figure 2. Quantitation of angiogenesis and of p53-positive keratinocytes in control- and carcinogen-treated skin xenografts. (a) Number of CD31-positive blood
vessels per field in control-, DMBA-, and DMBA plus TPA– treated human skin xenografts. (b) Number of p53 positive basal and squamous keratinocytes per field
in control, DMBA- and DMBA plus TPA– treated skin xenografts. *P < .05 and **P < .01 relative to control.
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to incipient SCC in human skin. In our experiments, no
differences were observed between the application of
DMBA alone and a two-stage system using DMBA initia-
tion and promotion by TPA. Previous studies showed that
in a xenograft model of human neonatal skin UVB promotion
is necessary to induce human squamous carcinoma [12]
and that topical application of a carcinogen alone is not
sufficient [13].
Our results reveal that molecular and microscopic
changes are detectable after carcinogen treatment alone,
although no frank carcinoma or premalignant papilloma were
seen. This was the case despite the fact that we used adult
human eyelid skin that had been exposed to a lifetime of
sunlight in contrast to the commonly used UV-naive neonatal
foreskin used in the aforementioned experiments. In our
model, immunostaining for PCNA demonstrated increased
and sustained proliferation of epidermal keratinocytes in the
basal layer, which led to some overall thickening of the skin
grafts. Despite this marked PCNA upregulation compared to
control skin, histologic changes such as papillomatosis were
observed only in mouse skin but not in the human xenografts.
Whereas the occurrence of murine papillomas already
5 weeks after the start of the treatment is early compared
to other studies [12,13], the lack of papillomas on the adult
human skin in our study is in agreement with earlier findings
with newborn skin [13] and indicates that UV light–exposed
human adult facial skin is more resistant to chemical carci-
nogens than murine skin. In general, our present findings
suggest that commonly used rodent models could overesti-
mate the carcinogenic potential of agents for humans [12].
In UV-induced skin cancers numerous characteristic ‘‘hot-
spots’’ for p53 point mutations have been described [39]. In
our experiments, high numbers of p53 immunopositive ker-
atinocytes in the human skin epidermis were observed as
late as 2 weeks after the end of treatment. The cause for p53
upregulation and stabilization in the carcinogen-treated tis-
sues is unclear. Acute induction of wild-type p53 by activated
ras has been observed [40], however, the prolonged pres-
ence of p53 very likely indicates a mutational cause [41,42].
FGF-1 and FGF-2 are present at significant concentra-
tions in most normal tissues in the adult and both factors
stimulate angiogenesis, cell proliferation, and motility, and
thus have the potential to play an important role during
tumorigenesis. However, under physiologic conditions the
activities of these FGFs are restricted by their immobilization
in the extracellular matrix [43]. Our previous studies show
that the FGF-BP studied here can serve as an activator of
FGFs by releasing these potent growth factors from their
extracellular matrix [25,34] and high levels of expression of
FGF-BP mRNA were observed in tumor tissues from
patients with SCC of the head and neck [25,27], and in
mouse skin papillomas [26]. Interestingly, the increase in
FGF-BP expression reached its maximum in early stages of
skin carcinogenesis in the mouse and decreased during
tumor progression, indicating that FGF-BP might play a role
especially during early stages of tumorigenesis [26]. This is
in agreement with our present findings in the human skin
xenotransplant model where FGF-BP upregulation occurs at
a very early time point of skin carcinogenesis and therefore
does fulfill the requirement of an angiogenic switch molecule
that is activated during the transition between premalignant
lesions and invasive carcinoma [15–17]. The underlying
molecular mechanisms that drive FGF-BP upregulation
may be due to a number of alterations in signal transduction
relevant for skin carcinogenesis and wound healing, e.g.,
through the EGF receptor, stress kinases, as well as
virally derived oncogenes that activate the FGF-BP promoter
[44–48].
In the present study, upregulation of FGF-BP was paral-
leled by a significant (2- to 2.5-fold) increase in the number of
blood vessels in carcinogen-treated skin just beneath the
basal membrane in the papillary dermis. Angiogenesis is
initiated early on during skin carcinogenesis [14] and accom-
panied by the upregulation of vascular endothelial growth
Figure 3. FGF-BP expression during wound healing and effects of FGF-BP on cell motility after ‘‘in vitro wounding’’ of a cell monolayer. (a) SCID mouse with
sutured human skin xenograft. (b) FGF-BP Northern blot of human skin xenografts at different time points of wound healing representing one of two experiments
with similar results. Quantitation after GAPDH control probing is also shown. (c) Different cell types 24 hours after ‘‘wounding’’ of confluent monolayers. SW-13
control or SW-13/FGF-BP transfected cells and mouse primary keratinocytes (MK) or dermal fibroblasts (MDF) with exogenously added control or FGF-BP–
containing media.
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factor (VEGF) observed in mice in premalignant papillomas
induced by chemical carcinogenesis and correlated with Ha-
ras activation [49]. In our human skin model, carcinogen
treatment induced angiogenesis at preneoplastic stages,
and this was accompanied by the upregulation of FGF-BP,
a protein that was also found upregulated in samples of
human SCC [25,27]. In line with this, a very recent study
found that FGF-BP positive human SCC samples also
showed a significant increased angiogenesis compared to
FGF-BP negative SCC [50]. It is likely that several indepen-
dent mechanisms contribute to the progression toward ma-
lignancy and our present findings support the notion of FGF-
BP as a contributor.
Interestingly, in nonmalignant diseases that include tissue
repair with altered FGF activity, changes in FGF-BP expres-
sion were also observed. In a collaborative effort we found a
strong upregulation of FGF-BP expression in the kidney
stroma of children with renal damage due to diverse causes
that include HIV infection as well as bacterial toxins causing
hemolytic uremia syndrome (HUS) [37]. In support of a role
of the increased FGF-BP expression during kidney repair,
we also observed an enhancement of FGF-induced kidney
epithelial proliferation by FGF-BP [37]. Furthermore, a very
recent report indicates that FGF-BP expression is found
upregulated in blood vessels of mice that succumb to pre-
mature atherogenesis [51]. In contrast to this long-term
upregulation of FGF-BP, the wound healing studies in mu-
rine and human tissues showed only a transient upregulation
of FGF-BP that returned to baseline on wound closure. It is
tempting to speculate that enhanced cell motility required for
proper wound closure could be mediated by the increased
production of FGF-BP.
In conclusion, we show how FGF-BP is differentially
regulated during wound healing and the onset of carcino-
genesis in human and murine skin. We propose a potential
role for this modulator of FGF activity and we show that the
human skin xenograft model can be used to identify early
molecular events during malignant transformation as well as
wound healing.
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